Pharmacokinetics of intravitreally administered VEGF inhibitors;Pharmakokinetik intravitreal applizierter VEGF-Inhibitoren

Ophthalmologe

Volumn 111, Issue 2, 2014, Pages 113-120

  Krohne, T U ^a   Holz, F G ^a   Meyer, C H ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Klinik Pallas AG   (Switzerland)

Author keywords

Aflibercept; Bevacizumab; Half life; Pegaptanib; Ranibizumab

Indexed keywords

BIOLOGICAL PRODUCT; EYE DROPS; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BIOLOGICAL MODEL; DRUG ABSORPTION; DRUG EFFECTS; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; RETINA;

ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL PRODUCTS; HUMANS; INTRAVITREAL INJECTIONS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; OCULAR ABSORPTION; OPHTHALMIC SOLUTIONS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893700522     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-013-2932-9     Document Type: Article

References (46)

1. Ahn J, Kim H, Woo SJ et al (2013) Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther 29(7):612-618
2. Bakbak B, Ozturk BT, Gonul S et al (2013) Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 29(8):728-732
3. Bakri SJ, Snyder MR, Reid JM et al (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182
4. Bakri SJ, Snyder MR, Reid JM et al (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-859
5. Basile AS, Hutmacher M, Nickens D et al (2012) Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration. J Clin Pharmacol 52:1186-1199
6. Bilsen K van, Hagen PM van, Bastiaans J et al (2011) The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha. Br J Ophthalmol 95:864-868
7. Busbee BG, Ho AC, Brown DM et al (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120:1046-1056
8. Carneiro AM, Costa R, Falcao MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25-e30
9. Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258-1267
10. Chin HS, Park TS, Moon YS et al (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25:556-560
11. Christoforidis JB, Williams MM, Wang J et al (2013) Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina 33:946-952
12. Csaky KG, Gordiyenko N, Rabena MG et al (2007) Pharmacokinetics of intravitreal bevacizumab in humans. Invest Ophthalmol Vis Sci 48: E-Abstract 4936
13. Doft BH, Weiskopf J, Nilsson-Ehle I et al (1985) Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 92:1601-1605
14. Durairaj C, Shah JC, Senapati S et al (2009) Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res 26:1236-1260
15. European Medicines Agency (2013) Eylea: EPAR - European public assessment report (September 20, 2012). Online verfügbar unter: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002392/WC500135744.pdf. (Zugegriffen: 7. Dezember 2013)
16. Eyetech Study Group (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143-152
17. Falavarjani KG, Modarres M, Nazari H (2010) Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye (Lond) 24:717-719
18. Gaudreault J, Fei D, Beyer JC et al (2007) Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260-1266
19. Gaudreault J, Fei D, Rusit J et al (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726-733
20. Jarus G, Blumenkranz M, Hernandez E et al (1985) Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology 92:91-96
21. Kakinoki M, Sawada O, Sawada T et al (2012) Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci 53:5877-5880
22. Kim H, Csaky KG, Chan CC et al (2006) The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 82:760-766
23. Kim H, Fariss RN, Zhang C et al (2008) Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 49:2025-2029
24. Krohne TU, Aisenbrey S, Holz FG (2012) Current therapeutic options in retinopathy of prematurity. Ophthalmologe 109:1189-1197
25. Krohne TU, Eter N, Holz FG et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508-512
26. Krohne TU, Liu Z, Holz FG et al (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682-686
27. Li H, Lei N, Zhang M et al (2012) Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 97:154-159
28. Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786
29. Matsuyama K, Ogata N, Matsuoka M et al (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215-1218
30. Mehta S, Blinder KJ, Shah GK et al (2010) Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging 41:323-329
31. Meyer CH, Krohne TU, Holz FG (2012) Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol 90:68-70
32. Mordenti J, Thomsen K, Licko V et al (1999) Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 52:101-106
33. Nomoto H, Shiraga F, Kuno N et al (2009) Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50:4807-4813
34. Sato T, Wada K, Arahori H et al (2011) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327-333
35. Sawada O, Kawamura H, Kakinoki M et al (2008) Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 246:1379-1381
36. Schmucker C, Ehlken C, Agostini HT et al (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7:e42701
37. Shah AR, Del Priore LV (2009) Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 93:1027-1032
38. Tan LE, Orilla W, Hughes PM et al (2011) Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles. Invest Ophthalmol Vis Sci 52:1111-1118
39. Teichmann KD (2002) Intravitreal injections: does globe size matter? J Cataract Refract Surg 28:1886-1889
40. Tucker CE, Chen LS, Judkins MB et al. (1999) Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732:203-212
41. Wu WC, Chen CC, Liu CH et al (2011) Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes. Invest Ophthalmol Vis Sci 52:6162-6167
42. Xu L, Lu T, Tuomi L et al (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616-1624
43. Xu Y, You Y, Du W et al (2012) Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci 53:5221-5226
44. Yanyali A, Aytug B, Horozoglu F et al (2007) Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144:124-126
45. Zehetner C, Kirchmair R, Huber S et al (2013) Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 97:454-459
46. Zhu Q, Ziemssen F, Henke-Fahle S et al (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115:1750-1755